{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:59:22Z","timestamp":1761893962513},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,6,11]],"date-time":"2004-06-11T00:00:00Z","timestamp":1086912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Cyclooxygenase\u20102 selective inhibitors were developed in order to reduce the incidence of life\u2010threatening gastrointestinal ulcer complications compared with non\u2010selective non\u2010steroidal anti\u2010inflammatory drugs. Previous outcomes studies have, variously, lacked power to investigate this endpoint, focused on broader outcomes, or been too small to quantify the influence of aspirin.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To evaluate lumiracoxib, a novel cyclooxygenase\u20102 selective inhibitor, vs. non\u2010selective non\u2010steroidal anti\u2010inflammatory drugs in an outcomes study of considerably increased size. This paper describes the study's methodology.<\/jats:p><jats:p><jats:bold>Methods and patients<\/jats:bold> :\u2002The Therapeutic Arthritis Research and Gastrointestinal Event Trial was a randomized, double\u2010blind, 52\u2010week study of lumiracoxib 400\u2003mg once daily (two to four times the recommended dose for osteoarthritis) versus naproxen 500\u2003mg twice daily or ibuprofen 800\u2003mg three\u2010times daily in patients with osteoarthritis. Randomization was stratified for low\u2010dose aspirin use and age (\u2264\u200364, 65\u201374, \u2265\u200375\u2003years). The study was powered to investigate upper gastrointestinal ulcer complications (primary endpoint) in patients not taking aspirin and in the overall study population; other endpoints included cardiovascular, renal and hepatic measures.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002Therapeutic Arthritis Research and Gastrointestinal Event Trial was designed to provide definitive answers concerning the gastrointestinal safety of lumiracoxib, addressing the controversial issues arising from outcomes studies with other cyclooxygenase\u20102 selective inhibitors.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.02026.x","type":"journal-article","created":{"date-parts":[[2004,7,2]],"date-time":"2004-07-02T05:54:26Z","timestamp":1088747666000},"page":"51-63","source":"Crossref","is-referenced-by-count":26,"title":["Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib \u2013 study design and patient demographics"],"prefix":"10.1111","volume":"20","author":[{"given":"C. J.","family":"Hawkey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Gitton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ehrsam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Huels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,6,11]]},"reference":[{"key":"e_1_2_42_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P"},{"key":"e_1_2_42_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402407"},{"key":"e_1_2_42_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.21907"},{"key":"e_1_2_42_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.4.600"},{"key":"e_1_2_42_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12154-2"},{"key":"e_1_2_42_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_42_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_42_9_2","unstructured":"LuHL.Statistical reviewer briefing document for the Advisory Committee. 14 June 2000. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b1_04_stats.doc. Accessed 14 April 2004."},{"key":"e_1_2_42_10_2","unstructured":"LiQ.Statistical reviewer briefing document for the Advisory Committee. 29 June 2000. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b2_04_stats.pdf. Accessed 14 April 2004."},{"key":"e_1_2_42_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.19.2398"},{"key":"e_1_2_42_12_2","unstructured":"VIOXX US Prescribing Information. Available athttp:\/\/www.vioxx.com\/vioxx\/shared\/documents\/english\/pi.pdf. Accessed 2 December 2003."},{"key":"e_1_2_42_13_2","first-page":"661","article-title":"COX\u20102 is not involved in thromboxane biosynthesis by activated human platelets","volume":"50","author":"Patrignani P","year":"1999","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_42_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10560"},{"issue":"1","key":"e_1_2_42_15_2","first-page":"S147","article-title":"Current perspective on the cardiovascular effects of coxibs","volume":"69","author":"Konstam MA","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"e_1_2_42_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200108093450607"},{"issue":"6","key":"e_1_2_42_17_2","first-page":"S15","article-title":"What have we learned from the large outcomes trials of COX\u20102 selective inhibitors? The rheumatologist's perspective","volume":"19","author":"Hochberg MC.","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"e_1_2_42_18_2","first-page":"259","article-title":"The in\u2010vitro and in\u2010vivo selectivity of lumiracoxib, a new and highly selective inhibitor of COX\u20102","volume":"61","author":"Marshall PJ","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_42_19_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.5.566"},{"issue":"4","key":"e_1_2_42_20_2","first-page":"A\u2010345","article-title":"Reduced cumulative incidence of gastroduodenal ulcers with two doses of a new coxib, COX189 compared with standard therapeutic doses of ibuprofen in osteoarthritis patients","volume":"122","author":"Hawkey CJ","year":"2002","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_2_42_21_2","first-page":"171","article-title":"Gastroduodenal safety and tolerability of lumiracoxib in patients with rheumatoid arthritis","volume":"62","author":"Kivitz AJ","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_42_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)00318-5"},{"key":"e_1_2_42_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01691.x"},{"key":"e_1_2_42_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290816"},{"key":"e_1_2_42_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780331101"},{"key":"e_1_2_42_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340502"},{"key":"e_1_2_42_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00387-3"},{"key":"e_1_2_42_28_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","journal-title":"BMJ"},{"key":"e_1_2_42_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780131308"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02026.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02026.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.02026.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:27:31Z","timestamp":1697419651000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.02026.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1111\/j.1365-2036.2004.02026.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02026.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,11]]}}}